Stock Analiz

Madrigal Pharmaceuticals, Inc. (MDGL) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was -$288M, a net margin of -30.1%; the best year in this period was 2016 with -$26M.

Over the twelve months to September 30, 2026, revenue was $1.4B and net income -$155M.

Free cash flow was -$190M in fiscal 2025 and positive in 0 of the 10 years shown.

The diluted share count rose 331% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2017: $0172018: $0182019: $0192020: $0202021: $0212022: $0222023: $0232024: $180M242025: $958M25$958M
Net income
2016: -$26M162017: -$31M172018: -$33M182019: -$84M192020: -$202M202021: -$242M212022: -$295M222023: -$374M232024: -$466M242025: -$288M25-$288M
Free cash flow
2016: -$18M162017: -$22M172018: -$26M182019: -$42M192020: -$158M202021: -$184M212022: -$225M222023: -$326M232024: -$457M242025: -$190M25-$190M
EPS (diluted)
2016: $-5.07162017: $-2.54172018: $-2.22182019: $-5.45192020: $-13.09202021: $-14.63212022: $-17.23222023: $-19.99232024: $-21.90242025: $-12.8525$-12.85

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$1.4B$958M$180M$0$0$0$0$0$0$0—
Gross profit——$174M$0$0——————
Operating income-$153M-$300M-$498M-$380M-$294M-$242M-$207M-$95M-$41M-$32M-$25M
Net income-$155M-$288M-$466M-$374M-$295M-$242M-$202M-$84M-$33M-$31M-$26M
EPS (diluted)$-5.85$-12.85$-21.90$-19.99$-17.23$-14.63$-13.09$-5.45$-2.22$-2.54$-5.07
R&D$388M$389M$237M$272M$245M$205M$185M$72M$25M$24M$16M
Revenue growth—+432.1%—————————

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$157M-$190M-$456M-$324M-$225M-$184M-$158M-$42M-$26M-$22M-$18M
Capital spending-$12M-$467000-$1M-$1M-$217000-$209000-$334000-$172000-$22000-$125000-$3000
Free cash flow-$169M-$190M-$457M-$326M-$225M-$184M-$158M-$42M-$26M-$22M-$18M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$134M$98M$80M$50M$32M$27M$21M$23M$13M$3M$8M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$984M$926M$634M$359M$270M$284M$439M$484M$192M$19M
Debt—$348M$120M$117M$70M$797000$786000$676000———
Equity—$603M$754M$405M$197M$196M$240M$417M$477M$182M$36M
Total assets—$1.3B$1.0B$641M$363M$273M$287M$442M$485M$192M$41M
Shares (diluted)30M22M21M19M17M17M15M15M15M12M5M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin——96.5%————————
Operating margin-10.7%-31.3%-276.4%————————
Net margin-10.9%-30.1%-258.6%————————
FCF margin-11.8%-19.8%-253.7%————————
ROIC—-24.9%-45.0%-57.5%-86.7%-97.3%-67.8%-18.0%-6.7%-13.9%-54.7%
ROE—-47.8%-61.8%-92.2%-149.6%-123.3%-84.3%-20.2%-6.9%-17.1%-72.5%

Frequently asked questions

What is Madrigal Pharmaceuticals’s annual revenue?

$958M in fiscal 2025 and $1.4B over the twelve months to September 30, 2026.

How much profit does Madrigal Pharmaceuticals make?

Net income was -$288M in fiscal 2025 (net margin -30.1%).

Is Madrigal Pharmaceuticals’s revenue growing?

Yes: revenue rose 432.1% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.